<DOC>
	<DOCNO>NCT00259857</DOCNO>
	<brief_summary>We previously evaluate safety efficacy Alendronate 10 patient juvenile osteoporosis 12-month clinical trial . We document Alendronate improve BMD spine hip without major side effect . There additional fracture therapy . The present study design evaluate safety efficacy Alendronate 20 child juvenile osteoporosis use double-blind , randomize , placebo-controlled , cross-over protocol .</brief_summary>
	<brief_title>Safety Efficacy Alendronate ( Fosamax ) Children With Osteoporosis</brief_title>
	<detailed_description>Osteoporosis uncommon disease child early adolescent . Patients low bone mineral density , develop fracture minimal trauma , frequently negative family history . The disease result either diminished bone formation increase bone removal ( resorption ) . No specific drug therapy recommend juvenile osteoporosis . Alendronate ( Fosamax ) effective inhibit bone resorption , increase BMD reduce fracture adult postmenopausal osteoporosis , become establish therapy child . In present study , plan evaluate safety efficacy Alendronate 20 patient juvenile osteoporosis two-year period . This randomized , double-blind , placebo-controlled protocol . In year-1 , 10 patient assigned receive Alendronate 10 patient placebo . In year-2 , patient cross second arm study . Those received Alendronate year-1 , receive placebo second year vice verse . The patient 5 visit , initial screen visit follow 4 post therapy visit six-month interval . Measurements include DXA bone density scan spine hip , urinalysis blood work .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<criteria>Eligibility Criteria : 515 yr age Weighing 20 kg History multiple fracture Tanner stage II le Osteoporosis DXA . Male female child history one atraumatic fracture , evidence one compression fracture radiographs spine ( reduction &gt; 20 percent ) . Bone Mineral Density ( BMD ) determine DXA sacn confirm osteoporosis Z score great 2 SD ( standard deviation ) normal mean age ( Z score &lt; 2 SD ) . Parental consent ( patient assent age 12 year ) participate study . Sexual development : Tanner stage II le ( Prepubertal stage ) . Weight = 20 kg . History severe gastritis reflux . Abnormalities esophagus delay emptying , strictures achalasia Marked kyphoscoliosis inability sit stand least 30 minute Hypersensitivity bisphosphonates Uncorrected hypocalcemia History gastric duodenal ulcer Renal dysfunction indicate serum Cr &gt; 1.5 mg/dl . Liver dysfunction indicate serum SGPT &gt; 2 time upper limit age serum total bilirubin &gt; 2.0 mg/dl . Diagnosis osteogenesis imperfecta , family history osteogenesis imperfecta , blue sclerae deafness . Diagnosis active rickets osteomalacia serum bone alkaline phosphatase 2 time great normal age . Pregnancy Anorexia Nervosa</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Fracture</keyword>
	<keyword>Bone Mineral Density</keyword>
	<keyword>DXA</keyword>
</DOC>